Dr. John Cush RheumNow
2 years 2 months ago
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Dr. John Cush RheumNow
2 years 2 months ago
DRESS - Drug Reaction With Eosinophilia and Systemic Symptoms - review on JAMA. Common drugs include allopurinol, Bactrim, Minocin, etc. https://t.co/1DmgyX33Cl
Dr. John Cush RheumNow
2 years 3 months ago
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS.
https://t.co/cTuIWU7eoa https://t.co/78kQvBGVzs
Dr. John Cush RheumNow
2 years 3 months ago
SLE Cost of Care and Disease Activity
A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity.
https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ
Dr. John Cush RheumNow
2 years 3 months ago
Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). They will conduct innovative research to uncover the underlying mechanisms and identify novel targets and pathways that could be harnessed to predict, monitor, and treat lupus, a complex autoimmune disease.
Dr. John Cush RheumNow
2 years 3 months ago
Greek cohort study of 570 SLE pts; lupus nephritis was initial presentation in 59, w/ another 66 LN during F/U (total LN= 22%). Predictors of LN: male sex (adjHR 4.31), Dx age <26yrs (3.71), Hi dsDNA (2.48), low C3/C4 (NS 2.24) https://t.co/lGmZlBpaPq https://t.co/XLqODDTnX6
Dr. John Cush RheumNow
2 years 3 months ago
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
https://t.co/oH5qdTvGY9 https://t.co/gTqIKemvOu
Dr. John Cush RheumNow
2 years 3 months ago
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/8QSZyzIVh9 https://t.co/WbSb2gcmHb
Dr. John Cush RheumNow
2 years 3 months ago
Upside/Downside of Steroids in Lupus Nephritis
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes.
https://t.co/6NR3obURAw https://t.co/YyYBg1TcYr
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
